Limited utility of imaging-based (N) markers in predicting cerebral spinal fluid Alzheimer’s disease biomarker positivity in lecanemab-eligible mild cognitive impairment
Relying on imaging-based (N) markers to select MCI patients who may be eligible for lecanemab prior to CSF biomarker testing may lead to inefficient diagnostic pathways and may fail to identify patients who could benefit from anti-Aβ therapy.
Authors
- Kenjiro Ono (ORCID: https://orcid.org/0000-0001-8454-6155)
- Moeko Noguchi‐Shinohara (ORCID: https://orcid.org/0000-0003-2883-1773)
- Satomi Kubota
- Daiki Shoji
- Hidetomo Murakami (ORCID: https://orcid.org/0000-0002-6551-4622)
- Takeshi Kuroda
- Yukiko Mori (ORCID: https://orcid.org/0000-0001-9486-9505)
Institutions
- Kanazawa University (JP)
- SHOWA Medical University (JP)
- SHOWA Medical University Fujigaoka Hospital (JP)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-12-04
- DOI
- https://doi.org/10.3389/fneur.2025.1735548
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Society for the Promotion of Science